<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26814">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004015</url>
  </required_header>
  <id_info>
    <org_study_id>RBM_WTR_2012-9</org_study_id>
    <nct_id>NCT02004015</nct_id>
  </id_info>
  <brief_title>Assessment Study of the Effect of NMBA on Bowel Peristalsis</brief_title>
  <acronym>CURARES</acronym>
  <official_title>Effect of an Induction Dose of Non Depolarizing Neuro Muscular Blocking Agents (NMBA) on Ultrasound Bowel Peristalsis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III prospective randomised study : curare vs placebo, comparing bowel peristalsis
      (abdominal echography) in the first minutes of after general anesthesia induction.

      Primary End Point: proportion of patients with a score of motion = 0
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary End Point Proportion of patients with a score of motion = 0

      Secondary End Point Time at which thumb adductor twitch measurement disappears (3rd
      consecutive measure with a twitch at 0) Mean minimal twitch measurement for those patients
      in who twitch measurement does not disappear Concordance study between twitch measurement
      and bowel peristalsis XML File Identifier: 1vUwHz2uUXeSc7soLu1cQwRAfcM= Page 15/24
      ultrasound score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients with a score of motion = 0</measure>
    <time_frame>10 minutes after NMBA or placebo injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with a score of motion = 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at which thumb adductor twitch measurement disappears</measure>
    <time_frame>1 month after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time at which thumb adductor twitch measurement disappears (3rd consecutive measure with a twitch at 0). Mean minimal twitch measurement for those patients in who twitch measurement does not disappear. Concordance study between twitch measurement and bowel peristalsis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Physiopathology</condition>
  <arm_group>
    <arm_group_label>Atracurium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROCURONIUM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection of placebo Injection in Intravenous bolus use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of placebo</intervention_name>
    <description>0.5 mg/kg milligram(s)/kilogram</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of NMBA</intervention_name>
    <arm_group_label>Atracurium</arm_group_label>
    <arm_group_label>ROCURONIUM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective surgery

          -  scheduled oro tracheal intubation

        Exclusion Criteria:

        Counter indication to NMBA:

          -  predicted difficult airway

          -  surgical counter indication: facial or laryngeal nerve function monitoring

          -  allergy to muscle relaxants neuro muscular disease Possible alteration of sensitivity
             to muscle relaxants due to ongoing medication: ex Valproate or aminoglycoside
             antibiotics. Predictable alteration of bowel movements or difficult abdominal
             ultrasound:

          -  scheduled abdominal surgery

          -  abdominal surgery in last month

          -  obesity: body mass index over 30 Full stomach or pregnancy requiring suxamethonium
             for intubation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Taylor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Taylor, MD</last_name>
    <phone>+33148036748</phone>
    <email>gtaylor@fo-rothschild.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>laurence Salomon, MD, PhD</last_name>
    <phone>+33148036431</phone>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Taylor</last_name>
      <phone>+33148036748</phone>
      <email>gtaylor@fo-rothschild.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Salomon</last_name>
      <phone>+33148036431</phone>
      <email>lsalomon@fo-rothschild.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Guillaume Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analytical</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Analgesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
